WO2002053616A1 - New linear block polymer - Google Patents

New linear block polymer Download PDF

Info

Publication number
WO2002053616A1
WO2002053616A1 PCT/SE2001/002901 SE0102901W WO02053616A1 WO 2002053616 A1 WO2002053616 A1 WO 2002053616A1 SE 0102901 W SE0102901 W SE 0102901W WO 02053616 A1 WO02053616 A1 WO 02053616A1
Authority
WO
WIPO (PCT)
Prior art keywords
linear polymer
amino
alkyl
formula
derived
Prior art date
Application number
PCT/SE2001/002901
Other languages
French (fr)
Inventor
Carl-Johan Aurell
Per Flodin
Original Assignee
Artimplant Ab
Carl-Johan Aurell
Per Flodin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0004925A external-priority patent/SE0004925L/en
Application filed by Artimplant Ab, Carl-Johan Aurell, Per Flodin filed Critical Artimplant Ab
Publication of WO2002053616A1 publication Critical patent/WO2002053616A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/42Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C08G18/4266Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
    • C08G18/4269Lactones
    • C08G18/4277Caprolactone and/or substituted caprolactone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/507Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08Processes
    • C08G18/10Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30Low-molecular-weight compounds
    • C08G18/38Low-molecular-weight compounds having heteroatoms other than oxygen
    • C08G18/3819Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen
    • C08G18/3823Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups
    • C08G18/3829Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups containing ureum groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30Low-molecular-weight compounds
    • C08G18/38Low-molecular-weight compounds having heteroatoms other than oxygen
    • C08G18/3819Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen
    • C08G18/3823Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups
    • C08G18/3831Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups containing urethane groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00Compositions for preparing biodegradable polymers

Definitions

  • the present invention relates to a new degradable linear polymer, a method for preparing and a method for processing said linear polymer, use of said linear polymer, implants for humans and animals, which implants comprise said linear polymer, and material for promoting wound healing in humans and animals, pharmaceutical preparations, microencapsules, suspensions, emulsions, porous three-dimensional structures, material or cell material, which all comprise said linear polymer.
  • SE, C2, 505703 or US, A, 6210441 describes a linear block polymer with a molecular weight of 10 4 Dalton, preferably 10 5 Dalton, comprising urea and urethane groups together incident and with ester groups at such a distance from each other that after hydrolysis of the same, fragments are created that are so small that they can be excreted from a human body.
  • Said linear block polymer comprising urea and urethane groups is suitable material for implants for humans and animals.
  • the present invention relates to a linear polymer with a molecular weight of at least 10 4 Dalton, which linear polymer consists of internally and linearly linked sequences, which sequences can be described according to Formula
  • R 2 80 to 100% of R 2 , which 80 to 100% of R 2 can be the same or different, comprise a segment according to Formula (2A)
  • E oxygen or nitrogen
  • X and Y which X and Y can be the same or different, are (C ⁇ -Cs)alkyl, or are derived from ((C ⁇ -C4)alkyl)[(2-4)-amino((C2-C ) alkanoate)],
  • Y is derived from a substituent according to Formula (3)
  • R is (C ⁇ -C )alkyl
  • I is from 1 to 20, and X is as has been defined above;
  • said 80 to 100% of R comprise a segment according to Formula (2B)
  • X ' is ((C ⁇ -C 5 )alkyl)
  • Z is hydrogen, (C C 4 )al yl, benzyl, tert. -butyl, phenacyl, isopropyl, neopentyl, sec-butyl or tosyl; and/or
  • said 80 to 100% of R 2 can be derived from a first group of diamine that are based on amino acids esterified with diols, and/or from a second group of diamines that are based on amino acids esterified with amino alcohols;
  • R 2 when not 100% of R 2 comprise a segment according to Formula (2A) or (2B), or can be derived from said first or second groups of diamines, each other R 2 can be derived from a third group of diamines that are aliphatic or aromatic diamines; and
  • each R-i can be derived from a diisocyanate, wherein said diisocyanate can be diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4 ' -diisocyanatobutane or 4,4 ' ,-dicyclohexylmethane diisocyanate (H 12 MDI), or said diisocyanate can be ethyl-2,6- diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4- diisocyanate (TDI) or 1 ,3-bis(isocyanatomethyl)cyclohexane.
  • MDI diphenylmethyl diisocyanate
  • HDI hexamethylene diisocyanate
  • HDI hexamethylene diisocyanate
  • H 12 MDI 4,4 ' ,-dicyclohexylmethane
  • Each alkyl and each alkanoate in Formula (1) can, independently of each other, be straight or branched, saturated or unsaturated, and/or substituted with, for example, methyl,. phenyl, 4-hydroxypheny ! l, 4-aminobutyl, 2-butyl, 2- hydroxymethyl, 3-aminopropyl, 2-aminoethyl, 2-mercaptomethyl, or similar.
  • R 2 comprises a segment
  • the term "comprises” is to be taken to denote that each alkyl and each alkanoate in the segment can be as described above.
  • Said linear polymer is degradable and is of the polyurea type when the polymer chain according to Formula (1 ) contains urea groups.
  • the urea groups in the polymer form intermolecular hydrogen bonds, which provides the cohesive forces that are required to hold the molecules together to a material. Furthermore, particularly strong intermolecular forces are obtained by the urea groups especially when several urea groups have the opportunity to interact. By giving several urea groups the opportunity to interact, a polymer is obtained that gives material that is stronger than material from polymers in which urea groups do not have the possibility to interact to the same extent.
  • Said linear polymer can be a block polymer or an alternating co-polymer.
  • the urea groups in said linear polymer are responsible for the cohesion of the material and the blocks in a block polymer that contain urea groups are often known as "hard".
  • the cohesion is a function of the number and lengths of the blocks that contain urea groups.
  • the "hard” block is the block that is comprised in R 2 and the neighbouring urea groups.
  • the blocks in a block polymer that give the material its extensibility and elasticity are known as "soft”.
  • a "soft" block can be comprised in Ri.
  • said degradable linear polymer according to the present invention is intended to be used in living tissue, in order to be subsequently eliminated when it has fulfilled its function, for example, a mechanical function. This is to take place through the polymer being degradable and being hydrolysed to fragments so small that these fragments can be transported away from- the location at which the polymer has been applied and excreted or metabolised.
  • the fragments are, for example, not to be larger than 2,000 Dalton, and should preferably be smaller than 1 ,000 Dalton.
  • hydrolysis occurs by the attack of water on ester groups in the chain of the linear polymer at pHs between 7.1 and 7.4, at a temperature of 37°C.
  • the end products and intermediates that are formed by hydrolysis of a linear polymer must not be toxic, and they must not irritate cells at the site of application or at other sites. It is very important to be able to vary the rate at which said linear polymer is degraded. Degradation of said linear polymer must not take place too rapidly, since the cells of the body must have sufficient time to carry out their repair work. Degradation that is too rapid has in several cases been shown to give such a high concentration of degradation products that these have caused damage to neighbouring tissue. On the other hand, it is not desirable that the mechanical properties should be maintained for an excessive period, since "stress shielding", and other effects, may arise, leading to degradation of tissue. An appropriate degradation time can be from approximately three months to approximately two years, depending on the application.
  • the chemical structure of the linear polymer determines its rate of degradation.
  • the structure of the ester groups primarily determines the rate of degradation, but the surroundings of the ester groups in the linear polymer also has a significant influence.
  • the chemical surroundings exert an influence through the balance between hydrophobic groups and hydrophilic groups, among other factors.
  • Said 80 to 100% of R 2 comprises one or several ester groups; wherein said linear polymer according to Formula (1 ) is degradable and comprises ester groups at such a distance from each other that after hydrolysis of said ester groups, fragments are created that are less than 2,000 Dalton, wherein the fragments can be excreted from a human or animal body.
  • the created fragments are preferably less than 1 ,000 Dalton.
  • the fragments can, according to the present invention, be in the order of 400-500 Dalton.
  • said ester groups may also make said linear polymer more solubje in water.
  • R 2 comprises a segment according to Formulas (2A), (2B) and/or can be derived from diamines that are based on amino acids esterified with diols, and/or from diamines that are based on amino acids esterified with amino alcohols, means that at least 80% of R 2 contains ester groups between the amino groups.
  • the fragments obtained after complete degradation (hydrolysis) of said linear polymer are sufficiently small, for example not larger than 2,000 Dalton and preferably less than 1 ,000 Dalton, which facilitates elimination of the degradation products when said linear polymer according to the invention is used in a human or animal body.
  • the size of the fragments that is, the size of the degradation products, makes a rapid and complete degradation of said linear polymer possible. Said linear polymer is degraded into such small fragments that further interaction between urea groups in the degradation products can be avoided. Interaction between urea groups in the degradation products would oppose a complete degradation.
  • E in Formula (2A) is oxygen.
  • X and Y in Formula (2A), the same or different are (C ⁇ -C )alkyl, or are derived from ((C ⁇ -C )alkyl)[(2-4)-amino((C2- C 4 ) alkanoate)], [(1-4)-amino((C ⁇ -C 4 )alkyl)]((C2-C 4 ) alkanoate), [(2-4)-amino((C 2 -C 4 ) alkanoate)]((C ⁇ -C 5 )alkyl) or ((C2-C 4 ) alkanoate)[(1-4)-amino((C 1 -C )alkyl)].
  • X and Y, the same or different, in Formula (2A) are (Ci-Csjalkyl, or are derived from ((C ⁇ -C 4 )alkyl)[(2-4)-amino((C2-C4) alkanoate)] or from
  • R in Formula (3) is (C 2 -C 6 )alkyl.
  • I in Formula (3) is from 1 to 10, or from 1 to 5.
  • X in Formula (2B) is ((C 2 -C 5 )alkyl).
  • the amino acids comprise from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
  • the diamines are based on amino acids esterified with diols, wherein the diols comprise from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
  • the diamines are based on amino acids esterified with amino alcohols, wherein the amino alcohols comprise from 2 to 20 carbon atoms, or from 2 to 15 carbon atoms, or more preferably, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
  • the diamines comprise from 2 to 30 carbon atoms, from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
  • Ri can be derived from a diisocyanate that comprises from 2 to 30 carbon atoms, from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
  • R2 comprises segments according to Formula (2A) and/or Formula (2B).
  • R 2 Another important group, from which said 80 to 100% of R 2 can be derived, is that of diamines according to Formula (4C). that are , based . p ⁇ protected amino acids according to Formula (4A) esterified with compounds (diols) according to Formula (4B) according to the following:
  • R ' is a protective group and amino acids according to Formula (4A) are ⁇ - and/or ⁇ -amino acids, examples of such amino acids are glycine (wherein R 3 is CH 2 ), alanine, lysine, ornithine, methionine, leucine, isoleucine, phenylalanine, tyrosine, glutamic acid or aspartic acid, or the esters of these with methyl, ethyl, benzyl, phenacyl, tert. -butyl, isopropyl, neopentyl, sec- butyl or tosyl in the ⁇ - or ⁇ -position, or from serine with a protected OH- group.
  • amino acids according to Formula (4A) are ⁇ - and/or ⁇ -amino acids, examples of such amino acids are glycine (wherein R 3 is CH 2 ), alanine, lysine, ornithine, methion
  • Diols according to Formula (4B) can, for example, be selected from ethylene glycol, propylene glycol, butanediol, pentanediol, hexanediol, neopentyl glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, polyethylene glycol (PEG), polytetramethylene oxide diol (PTMOG), 1 ,4-dihydroxymethyl benzene, polypropylene glycol and hydroxitelechelic polybutadiene, together with hybrids of these.
  • PEG polyethylene glycol
  • PTMOG polytetramethylene oxide diol
  • 1 ,4-dihydroxymethyl benzene polypropylene glycol and hydroxitelechelic polybutadiene, together with hybrids of these.
  • compounds according to Formula (4B) can be, for example, hydroxitelechelic oligomers (that is, oligomers with hydroxyl groups at both ends). Examples of such are hydroxitelechelic oligoesters, oligoamides and oligocarbonates.
  • Compounds according to Formula (4B) can also contain other heteroatoms, such as S or N arid/or ester g ti ⁇ ps; one example of which is 3-( ⁇ [(ferf-butoxycarbonyl)amino]actetyl ⁇ oxy)-2,2- bis(hydroxymethyl)propyl[(te/ ⁇ -butoxycarbonyl)amino] acetate.
  • R 2 Another important group from which said 80 to 100% of R 2 can be derived is the group of diamines that are derived from esters of protected amino acids according to Formula (4A), wherein the protected amino acids are esterified with amino alcohols.
  • One example is the glycine ester of ethanolamine.
  • Important criteria for the choice of diamines from which said 80 to 100% of R2 can be derived are the length of the chain of the diamine, the stiffness of the chain, the chemical structure of the ester group and its chemical surroundings.
  • R 2 in which said 80 to 100% of R 2 is not equal to 100%, can, the same or different, be derived from aliphatic or aromatic diamines, wherein examples of such diamines are primary diamines, for example, ethylene diamine, 1 ,3-diaminopropane, 1 ,3-diamino-2-hydroxypropane, 1 ,3-propandiol-bis-p-amino benzoate or ethylene glycolbisglycine ester diamine.
  • diamines are primary diamines, for example, ethylene diamine, 1 ,3-diaminopropane, 1 ,3-diamino-2-hydroxypropane, 1 ,3-propandiol-bis-p-amino benzoate or ethylene glycolbisglycine ester diamine.
  • Said diisocyanates from which Ri can be derived can be commercially available, such as diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4'-diisocyanatobutane or 4,4',-dicyclohexylmethane diisocyanate (H 12 MDI), or said diisocyanate can be ethyl-2,6- diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4- diisocyanate (TDI) or 1 ,3-bis(isocyanatomethyl)cyclohexane.
  • MDI diphenylmethyl diisocyanate
  • HDI hexamethylene diisocyanate
  • HDI hexamethylene diisocyanate
  • H 12 MDI 4,4',-dicyclohexylmethane diisocyanate
  • a yet further embodiment according to the present invention relates to a linear polymer wherein said linear polymer is a block polymer.
  • An embodiment according to the present invention relates to a linear polymer wherein said 80 to 100% of R , the same or different, can be derived from diamines according to Formula (4C)
  • R ' is a protective group and amino acids according to Formula (4A) are ⁇ - and/or ⁇ -amino acids, preferably glycine (wherein R 3 is CH 2 ), alanine, lysine, ornithine, methionine, leucine, isoleucine, phenylalanine, tyrosine, glutamic acid or aspartic acid, or the esters of these with methyl, ethyl, benzyl, phenacyl, tert.-butyl, isopropyl, neopentyl, sec-butyl or tosyl in the ⁇ - or ⁇ -position, or from serine with a protected OH-group, and
  • diols according to Formula (4B) are selected from ethylene glycol, propylene glycol, butanediol, pentanediol, hexanediol, neopentyl glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, polyethylene glycol (PEG), polytetramethylene oxide diol (PTMOG) , 1 ,4-dihydroxymethylbenzene, polypropylene glycor and.hydroxitelechelic polybutadiene, and also hybrids of these, and from hydroxitelechelic oligomers, preferably hydroxitelechelic oligoesters, oligoamides or oligocarbonates, wherein the compounds according to Formula (4B) can also contain heteroatoms, such as S or N and/or ester groups.
  • heteroatoms such as S or N and/or ester groups.
  • a further embodiment according to the present invention relates to a linear polymer, wherein said 80 to 100% of R 2 , the same or different, can be derived from diamines that are derived from esters of amino acids with amino alcohols, for example the glycine ester of ethanolamine or 3-( ⁇ [(fetf-butoxycarbonyl)amino]actetyl ⁇ oxy)-2,2- bis(hydroxymethyl)propyl[(te/ ⁇ -butoxycarbonyl)amino] acetate.
  • a yet further embodiment according to the present invention relates to a linear polymer wherein each R1 , the same or different, can be derived from a diisocyanate, which diisocyanate may be commercially available, such as diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4 ' - diisocyanatobutane or 4,4 ' ,-dicyclohexylmethane diisocyanate (H ⁇ 2 MDI), or said diisocyanate can be ethyl-2,6-diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4-diisocyanate (TDI) or 1 ,3- bis(isocyanatomethyl)cyclohexane.
  • MDI diphenylmethyl diisocyanate
  • HDI hexamethylene diisocyanate
  • HDI he
  • a yet further embodiment relates to a linear polymer according to Formula (1 ), wherein said 80 to 100% of R 2 , which 80 to 100% of R 2 can be the same or different, can be derived from one or several of
  • Said linear polymer according to the present invention is of the polyurea type and can be prepared from the reaction between one or several different diisocyanates and one or several different diamines, wherein closely equivalent amounts of isocyanate and amino groups are required.
  • the reaction is carried out either in solution or through phase interface polymerisation.
  • the reactants are soluble in the solvent while the linear polymer formed can be either soluble or it can precipitate.
  • two immiscible solvents are used, each of which dissolves one of the reactants.
  • Polymerisation occurs at the interface between the phases, from which the name of this procedure is derived.
  • the molecular weight of the linear polymerjhat js formed can be regulated by modifying the stochiometric balance or by the addition of what are known as chain-stoppers, such as primary or secondary monoamines.
  • the molecular weight distribution is influenced by the method of polymerisation and can be modified by extraction with solvent for, for example, low molecular weight fractions, or by precipitation of high molecular weight fractions from the solution of the linear polymer.
  • the present invention also relates to a method for preparing said linear polymer, wherein said method comprises polymerisation, in which approximately n moles of one or several different diamines, that is, compounds according to Formula (5)
  • Ri and R 2 are defined as they have been previously.
  • molar ratios for -NH /-NCO are used from 0.95 to 1.05 in the above-described polymerisation.
  • Polyureas are known to be difficult to process in that the melting point is higher than the " temperature at which' degradation ' starts to occur. Due to the tendency of the urea groups to interact via hydrogen bonds, polyureas have a strong tendency to form gels in solution and are difficult to dissolve at all. This can be counteracted to a certain extent by the addition of agents that interact with the urea groups, for example LiCI, LiBr, urea or guanidine hydrochloride. The dissolving can thus take place in dimethylformamide in which LiCI has been dissolved to give a concentration of 1-5%.
  • agents that interact with the urea groups for example LiCI, LiBr, urea or guanidine hydrochloride.
  • the dissolving can thus take place in dimethylformamide in which LiCI has been dissolved to give a concentration of 1-5%.
  • the interaction between urea groups in said linear polymer can be influenced by the chemical structure of the urea groups or in their vicinity.
  • said linear polymer according to the present invention through said Ri and/or said 80 to 100% of R 2 , comprises parts that can be derived from amino acids, substituents of ⁇ -carbon atoms in these amino acids lead to steric hindrance, giving weaker hydrogen bonds as a consequence.
  • interaction between stereoisomers can give increased close-packing, and consequently a stronger interaction between polymer chains.
  • a further embodiment according to the present invention relates to a linear polymer, wherein said Ri and/or said 80 to 100% of R 2 comprise parts that can be derived from amino acids, wherein said parts comprise amino acids with substituents on their ⁇ -carbon atoms.
  • the present invention relates to an embodiment of said linear polymer, wherein said 80 to 100% of R 2 is 100%, which means that said other R 2 is not present, that is, the amount of said other R 2 is zero.
  • a yet further embodiment according to the present invention relates to a linear polymer, wherein the each of said alkyls and each of said alkanoates in Formula (1 ) can, independently of each other, be straight or branched, saturated or unsaturated, and/or substituted with, for example, methyl, phenyl, 4-hydroxyphenyl, 4-aminobutyl, 2-butyl, 2-hydroxy methyl, 3- aminopropyl, 2-aminoethyl,.2-mercaptomethyl, or similar.. ⁇ -,-. -.- "
  • Fibres can thus be prepared by dry or wet spinning, that is, the extrusion of the polymer solution through a mouthpiece with removal of the solvent either by evaporation or by precipitation by non-solvent.
  • Films can be prepared in a similar manner by spreading out the polymer solution in a thin layer on a plate, followed by evaporation and/or precipitation. Naturally, this can take place continuously on a cylinder or an infinite loop in combination with an oven.
  • One method for preparing hollow articles is by dipping, that is, a mould is repeatedly dipped into the polymer solution and dried and/or coagulated between each dipping. The mould is subsequently removed, which can take place by dissolving it, melting it, or by a mechanical method.
  • the polymer can be applied to, for example, woven fabric, film or surfaces by, for example, coating, impregnation, lamination or casting, followed by evaporation of the solvent and/or coagulation with a non-solvent.
  • the present invention also relates to a method for processing said linear polymer, wherein said method comprises preparing fibres through dry or wet spinning of said linear polymer.
  • a yet further embodiment according to the present invention relates to a method for processing said linear polymer, wherein said method comprises preparing film of said linear polymer or application of said linear polymer onto, for example, woven fabric, film or surfaces by, for example, coating, impregnation, lamination or casting.
  • a further embodiment according to the present invention relates to a method for processing said linear polymer, wherejn said method comprises dipping of a mould that is dipped into a solution of said linear polymer.
  • the present invention also relates to the use of said linear polymer described above, in the form of, for example, fibres or film, as, for example, material in implants for humans and animals, for example, as implants for tendons, ligaments, blood vessels, sutures, discs or menisci, for pharmaceutical preparations, in microencapsulation, in suspensions, in emulsions, in porous three-dimensional materials, such as porous polymers materials, or similar.
  • Porous polymer material is described in, for example, Swedish patent application SE, A, 0004856-1 , which is here referred to in its entirety.
  • SE, A, 0004856-1 describes among other things a method for preparing an open porous polymer material.
  • Swedish patent application SE, C2, 514064, which describes porous films, is also referred to here in its entirety.
  • the invention relates to the use of said linear polymer according to the present invention in, for example, pharmaceutical preparations, during microencapsulation, in suspensions, in emulsions or similar.
  • the present invention also relates to the use of said linear polymer as material for artificial blood vessels, in order to prevent adhesions, as an obstacle to adhesion or in order to promote wound healing in humans and animals.
  • a further embodiment according to the present invention relates to the use of said linear polymer as cell material for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering”.
  • the invention relates to implants, for example, for tendons, ligaments, blood vessels, sutures, discs or menisci, for humans and animals, wherein said implants comprise said linear polymer.
  • the present invention also relates to pharmaceutical preparations, microencapsules, suspensions, emulsions or porous three-dimensional structures that comprise said linear polymer.
  • the present invention also relates to material for artificial blood vessels, in order to prevent adhesions, as an obstacle to adhesion or in order to promote wound healing in humans and animals, wherein said material comprises said linear polymer.
  • the present invention relates to a cell material for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering", wherein said cell material comprises said linear polymer.
  • Polyureas in the form of fibres can be used in ligaments, tendons, sutures or porous three-dimensional structures. In combination with impregnation or lamination, they can be used as, for example, artificial blood vessels or to prevent adhesions.
  • They can be used in the form of film for, for example, culturing of cells, as an adhesion obstacle or for wound treatment.
  • tissue engineering As cell material they can be used as the matrix for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering”.
  • the material can be adapted to different applications by varying its degradation time with the aid of the chemical structure.
  • the temperature in the reactor rose rapidly to 10°C, after which it sank to its original value.
  • the reaction was allowed to proceed for 3 hours at 0°C, after which it was warmed to approximately 30°C for one hour, and then left under stirring at room temperature until the next day.
  • Processing of the reaction mixture commenced with filtration through a 40-100 ⁇ m glass filter, wherein the filtration separates out precipitated dicyclohexylurea (DCU).
  • the dichloromethane that passed the filter was extracted with a 1M potassium hydrogen "sulphate solution, followed by extraction with distilled water and with a saturated sodium hydrogen carbonate solution. The dichloromethane phase was then washed three times with distilled water.
  • the washed dichloromethane phase was dried over water-free magnesium sulphate and evaporated to give an oil that crystallised slowly. Yield 80-90%. If the oil contains contaminant in the form of dicyclohexylurea, the oil can be dissolved in ethyl acetate and the contaminant filtered out, in order to then evaporate off the ethyl acetate and regain the final product in a more pure condition. Yield: 16.4 g (approximately 80%).
  • the reaction mixture was processed by filtering out the DCU that had formed, after which the remaining solution was washed by extraction with a 1M potassium hydrogen sulphate solution, distilled water, saturated sodium hydrogen carbonate and, finally, three times with distilled water.
  • the thus purified organic phase was then dried over water-free magnesium sulphate, filtered and then evaporated to give a colourless oil that crystallised on reaching room temperature.
  • the reaction mixture was warmed for a short period to 30°C before processing. After cooling, the DCU was filtered out and the residue washed by extraction with potassium hydrogen sulphate (1 M), distilled water, sodium hydrogen carbonate (saturated) and three times with distilled water. The organic phase was then dried over water-free magnesium sulphate and evaporated to give an oil. The oil was dissolved in absolute ethanol and placed in the cold to crystallise. The crystals were filtered out and dried. Yield: approximately 8 g (theoretical 8.8 g) 90%.
  • the mixture was processed after being warmed to 30°C for approximately one hour. The residue was dissolved in ethyl acetate after filtering and evaporation, on which further DCU precipitated out. The product mixture was allowed to stand for three days before being refiltered. The reaction mixture was washed by extraction with potassium hydrogen sulphate (1 M), distilled water, sodium hydrogen carbonate (saturated) and finally three times with distilled water. The organic phase was then dried over water-free magnesium sulphate, filtered and evaporated to dryness.
  • Pd/C 10% palladium on active carbon
  • Acetone (10 ml) was added after stirring for 20 minutes, and then deionised water (200 ml). The water was separated out and new water (200 ml) added.
  • This water also was separated out and the sticky mass of polymer dried in a vacuum oven.
  • the dried polymer was dissolved in DMSO to a concentration of 18% and it was possible to cast a film.
  • a sample of the dried polymer was subjected to analysis by SEC ("Size Exclusion Chromatography"). According to SEC (using an RI detector) the polymer has a peak after approximately 15.0 minutes, which corresponds to a molecular weight of 180,000 relative to a polystyrene standard.
  • SEC Size Exclusion Chromatography
  • MDI was weighed out into a 250 ml flanged flask, nitrogen gas was applied.
  • Triethylamine and chloroform were added dropwise using a pipette during approximately 3 minutes, under stirring.
  • Acetone (8 ml) was added after stirring for 20 minutes, and then deionised water (200 ml). The water was separated out and new water (200 ml) added. This water also was separated out and the organic phase was then evaporated in a Rotavapor. A yellow-white powder was obtained.
  • the dried polymer was dissolved in DMSO to a concentration of 18% and it was possible to cast a film.
  • a sample of the dried polymer was subjected to analysis by SEC. According to SEC (using UV and RI detectors) the polymer has a peak after approximately 14.13 minutes, which corresponds to a molecular weight of 400,000 relative to a polystyrene standard.
  • 4-[(2-aminoacetyl)oxy]butyl aminoacetate was prepared in analogy with the preparation according to Examples 1-6. Thereafter, a linear polymer is prepared in analogy with Example 7 by the polymerisation of L-lysine diisocyanate (LDI) with 4-[(2-aminoacetyl)oxy]butyl aminoacetate.
  • L-lysine diisocyanate L-lysine diisocyanate
  • the linear polymer prepared was in the form of a film and had a molecular weight of 450,000 relative to a polystyrene standard. The polymer, was held in a bath with phosphate buffer (at pH 7.0) at 67°C.
  • the polymer film had disintegrated after seven days, that is, it was broken down to such a degree that it was not possible to obtain a sample for analysis by SEC.
  • 4-[(2-aminoacetyl)oxy]butyl aminoacetate was prepared in analogy with the preparation according to Examples 1-6. Thereafter, a linear polymer is prepared in analogy with Example 8 by the polymerisation of 4,4 ' -diphenylmethane diisocyanate (MDI) with the HCI salt of 4-[(2- aminoacetyl)oxy]butyl aminoacetate.
  • MDI 4,4 ' -diphenylmethane diisocyanate
  • HCI salt of 4-[(2- aminoacetyl)oxy]butyl aminoacetate was in the form of a film and had a molecular weight of 400,000 relative to a polystyrene standard.
  • the polymer was held in a bath with phosphate buffer (at pH 7.0) at 67°C. A sample for SEC analysis was taken after five days in the phosphate buffer, wherein the molecular weight was reduced to 175,000 relative to a polystyrene standard.
  • 4-[(2-amino-4-methylpentanoyl)oxy]b,utyl . , 2-amino-4-methylpentanoate is prepared in analogy with the preparation according to Examples 1-6. Thereafter, a linear polymer is prepared in analogy with Example 8 by the polymerisation of 4,4'-diphenylmethane diisocyanate (MDI) with the HCI salt of 4-[(2-amino-4-methylpentanoyl)oxy]butyl 2-amino-4-methylpentanoate.
  • MDI 4,4'-diphenylmethane diisocyanate
  • HCI salt of 4-[(2-amino-4-methylpentanoyl)oxy]butyl 2-amino-4-methylpentanoate was in the form of a film and had a molecular weight of 435,000 relative to a polystyrene standard.
  • the polymer was held in a bath with phosphate buffer (at pH 7.0) at 67°C. SEC analysis was carried out after 55 days, and the molecular weight had then been reduced to between 200,000 and 300,000 relative to a polystyrene standard.

Abstract

The present invention relates to a linear polymer with a molecular weight of at least 104 Dalton, which linear polymer consists of internally and linearly linked sequences, which sequences can be described according to Formula (1) wherein 80 to 100% of R¿2?, which 80 to 100% of R2 can be the same or different, comprise segments that are derived from diamines, which diamines comprise ester groups, and each R1, the same or different, can be derived from diisocyanate, and a method for preparing and a method for processing said linear polymer, use of said linear polymer, implants for humans and animals, material for promoting wound healing in humans and animals, and also pharmaceutical preparations, microencapsules, suspensions, emulsions, porous three-dimensional structures, material or cell material, which all comprise said linear polymer.

Description

NEW LINEAR BLOCK POLYMER
FIELD OF THE INVENTION
The present invention relates to a new degradable linear polymer, a method for preparing and a method for processing said linear polymer, use of said linear polymer, implants for humans and animals, which implants comprise said linear polymer, and material for promoting wound healing in humans and animals, pharmaceutical preparations, microencapsules, suspensions, emulsions, porous three-dimensional structures, material or cell material, which all comprise said linear polymer.
PRIOR ART
In the event of human or animal injury or disease, damaged organs or damaged tissue must on occasions be temporarily or permanently replaced by some form of implant. In order for the function of such an implant to be acceptable, not only must the implant have properties, for example strength, that enable it to replace the functions of the damaged organ or tissue, and it must also be biocompatible. Various materials such as pure titanium and certain plastics have been shown to have acceptable function, and are extensively used. It is often desirable that an implant promotes growth of damaged tissue, while at the same time the implant should, in many cases, be biologically degradable.
SE, C2, 505703 or US, A, 6210441 , describes a linear block polymer with a molecular weight of 104 Dalton, preferably 105 Dalton, comprising urea and urethane groups together „and with ester groups at such a distance from each other that after hydrolysis of the same, fragments are created that are so small that they can be excreted from a human body. Said linear block polymer comprising urea and urethane groups is suitable material for implants for humans and animals. DESCRIPTION OF THE INVENTION
The present invention relates to a linear polymer with a molecular weight of at least 104 Dalton, which linear polymer consists of internally and linearly linked sequences, which sequences can be described according to Formula
(1 )
Figure imgf000003_0001
(1 ) wherein
80 to 100% of R2, which 80 to 100% of R2 can be the same or different, comprise a segment according to Formula (2A)
Figure imgf000003_0002
wherein
E is oxygen or nitrogen,
X and Y, which X and Y can be the same or different, are (Cι-Cs)alkyl, or are derived from ((Cι-C4)alkyl)[(2-4)-amino((C2-C ) alkanoate)],
[(1 -4)-amino((Cι-C4)alkyl)]((C2-C ) alkanoate),
[(2-4)-amino((C2-C4) alkanoate)]((Cι-C5)alkyl),
((C2-C4) alkanoate)[(1-5)-amino((CrC5)alkyl)],
((Cι-C4)alkyl)[(2-4)-amino((C2-C4) carboxamide)],
[(1-4)-amino((Cι-C4)alkyl)]((C2-C4) carboxamide),
[(2-4)-amino((C2-C4) carboxamide)]((Cι-C5)alkyl) or from
((C2-C4) carboxamide)[(1 -5)-amino((C1-C5)alkyl)], and provided that Y is not Ci-alkyl, or
Y is derived from a substituent according to Formula (3)
Figure imgf000004_0001
(3)
wherein R is (Cι-C )alkyl, and
I is from 1 to 20, and X is as has been defined above;
said 80 to 100% of R , the same or different, comprise a segment according to Formula (2B)
Figure imgf000004_0002
wherein X' is ((Cι-C5)alkyl) and
Z is hydrogen, (C C4)al yl, benzyl, tert. -butyl, phenacyl, isopropyl, neopentyl, sec-butyl or tosyl; and/or
said 80 to 100% of R2, the same or different, can be derived from a first group of diamine that are based on amino acids esterified with diols, and/or from a second group of diamines that are based on amino acids esterified with amino alcohols; and
when not 100% of R2 comprise a segment according to Formula (2A) or (2B), or can be derived from said first or second groups of diamines, each other R2 can be derived from a third group of diamines that are aliphatic or aromatic diamines; and
each R-i, the same or different, can be derived from a diisocyanate, wherein said diisocyanate can be diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4'-diisocyanatobutane or 4,4',-dicyclohexylmethane diisocyanate (H12MDI), or said diisocyanate can be ethyl-2,6- diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4- diisocyanate (TDI) or 1 ,3-bis(isocyanatomethyl)cyclohexane.
When X and/or Y in Formula (2A) is or are "derived from", the amino group that is part of the moiety that X or Y is derived from forms the respective amine bond with R2 in Formula (1 ). In the same way, when R2 can be "derived from" diamines, the amines that are part of the diamines form the amine bonds to R2 in Formula (1). Furthermore, R, can be "derived from" a diisocyanate, wherein each isocyanate gives rise to urea bonding with R2 in Formula (1). In other words, links of urea are formed that join together Ri and R2 in Formula (1 ).
Each alkyl and each alkanoate in Formula (1) can, independently of each other, be straight or branched, saturated or unsaturated, and/or substituted with, for example, methyl,. phenyl, 4-hydroxypheny!l, 4-aminobutyl, 2-butyl, 2- hydroxymethyl, 3-aminopropyl, 2-aminoethyl, 2-mercaptomethyl, or similar. When R2 comprises a segment, the term "comprises" is to be taken to denote that each alkyl and each alkanoate in the segment can be as described above. Said linear polymer is degradable and is of the polyurea type when the polymer chain according to Formula (1 ) contains urea groups. The urea groups in the polymer form intermolecular hydrogen bonds, which provides the cohesive forces that are required to hold the molecules together to a material. Furthermore, particularly strong intermolecular forces are obtained by the urea groups especially when several urea groups have the opportunity to interact. By giving several urea groups the opportunity to interact, a polymer is obtained that gives material that is stronger than material from polymers in which urea groups do not have the possibility to interact to the same extent. Said linear polymer can be a block polymer or an alternating co-polymer. The urea groups in said linear polymer are responsible for the cohesion of the material and the blocks in a block polymer that contain urea groups are often known as "hard". In a block polymer, the cohesion is a function of the number and lengths of the blocks that contain urea groups. When said linear polymer according to Formula (1 ) is a block polymer, the "hard" block is the block that is comprised in R2 and the neighbouring urea groups. In a corresponding manner, the blocks in a block polymer that give the material its extensibility and elasticity are known as "soft". When said linear polymer according to Formula (1) is a block polymer, a "soft" block can be comprised in Ri.
Furthermore, said degradable linear polymer according to the present invention is intended to be used in living tissue, in order to be subsequently eliminated when it has fulfilled its function, for example, a mechanical function. This is to take place through the polymer being degradable and being hydrolysed to fragments so small that these fragments can be transported away from- the location at which the polymer has been applied and excreted or metabolised. The fragments are, for example, not to be larger than 2,000 Dalton, and should preferably be smaller than 1 ,000 Dalton. In humans, for example, hydrolysis occurs by the attack of water on ester groups in the chain of the linear polymer at pHs between 7.1 and 7.4, at a temperature of 37°C. The end products and intermediates that are formed by hydrolysis of a linear polymer must not be toxic, and they must not irritate cells at the site of application or at other sites. It is very important to be able to vary the rate at which said linear polymer is degraded. Degradation of said linear polymer must not take place too rapidly, since the cells of the body must have sufficient time to carry out their repair work. Degradation that is too rapid has in several cases been shown to give such a high concentration of degradation products that these have caused damage to neighbouring tissue. On the other hand, it is not desirable that the mechanical properties should be maintained for an excessive period, since "stress shielding", and other effects, may arise, leading to degradation of tissue. An appropriate degradation time can be from approximately three months to approximately two years, depending on the application. Furthermore, the chemical structure of the linear polymer determines its rate of degradation. The structure of the ester groups primarily determines the rate of degradation, but the surroundings of the ester groups in the linear polymer also has a significant influence. The chemical surroundings exert an influence through the balance between hydrophobic groups and hydrophilic groups, among other factors.
Said 80 to 100% of R2, the same or different, comprises one or several ester groups; wherein said linear polymer according to Formula (1 ) is degradable and comprises ester groups at such a distance from each other that after hydrolysis of said ester groups, fragments are created that are less than 2,000 Dalton, wherein the fragments can be excreted from a human or animal body. The created fragments are preferably less than 1 ,000 Dalton. For example, the fragments can, according to the present invention, be in the order of 400-500 Dalton. Furthermore, said ester groups may also make said linear polymer more solubje in water.
The fact that at least 80% of R2 comprises a segment according to Formulas (2A), (2B) and/or can be derived from diamines that are based on amino acids esterified with diols, and/or from diamines that are based on amino acids esterified with amino alcohols, means that at least 80% of R2 contains ester groups between the amino groups. In this way, the fragments obtained after complete degradation (hydrolysis) of said linear polymer are sufficiently small, for example not larger than 2,000 Dalton and preferably less than 1 ,000 Dalton, which facilitates elimination of the degradation products when said linear polymer according to the invention is used in a human or animal body. The size of the fragments, that is, the size of the degradation products, makes a rapid and complete degradation of said linear polymer possible. Said linear polymer is degraded into such small fragments that further interaction between urea groups in the degradation products can be avoided. Interaction between urea groups in the degradation products would oppose a complete degradation.
It is preferred that E in Formula (2A) is oxygen.
Furthermore, it is preferable that X and Y in Formula (2A), the same or different, are (Cι-C )alkyl, or are derived from ((Cι-C )alkyl)[(2-4)-amino((C2- C4) alkanoate)], [(1-4)-amino((Cι-C4)alkyl)]((C2-C4) alkanoate), [(2-4)-amino((C2-C4) alkanoate)]((Cι-C5)alkyl) or ((C2-C4) alkanoate)[(1-4)-amino((C1-C )alkyl)].
Furthermore, another preferred embodiment is that X and Y, the same or different, in Formula (2A) are (Ci-Csjalkyl, or are derived from ((Cι-C4)alkyl)[(2-4)-amino((C2-C4) alkanoate)] or from
[(2-4)-amino((C2-C4) alkanoate)]((Cι-C5)alkyl).
When X and/or Y in Formula (2A) is or are derived from ((Cι-C4)alkyl)[(2-4) amino((C2-C4) alkanoate)], then ((Cι-C )alkyl)[(3-4)-amino((C3-C4) alkanoate)] is preferred.
Furthermore, when X and/or Y in Formula (2A) is or are derived from [(1-4)-amino((Cι-C4)alkyl)]((C2-C ) alkanoate), then [(1-4)-amino((Cι-C )alkyl)]((C3-C4) alkanoate) is preferred. Furthermore, when X and/or Y in Formula (2A) is or are derived from [(2-4)-aιmino((C2-C4) alkanoate)]((Cι-C5)alkyl), then [(2-4)-amino((C2-C4) alkanoate)]((C2-C5)alkyl) is preferred.
When X and/or Y in Formula (2A) is or are derived from ((C2-C4) alkanoate)[(1-5)-amino((Cι-C5)alkyl)], then ((C2-C4) alkanoate)[(2-5)-amino((C2-C5)alkyl)] is preferred.
When X and/or Y in Formula (2A) is or are derived from ((Cι-C )alkyl)[(2-4)-amino((C2-C4) carboxamide)], then ((Cι-C4)alkyl)[(3-4)-amino((C3-C4) carboxamide)] is preferred.
Furthermore, when X and/or Y in Formula (2A) is or are derived from [(1-4)-amino((Cι-C4)alkyl)]((C2-C4) carboxamide), then
[(1-4)-amino((Cι-C4)alkyl)]((C3-C4) carboxamide) is preferred.
Furthermore, when X and/or Y in Formula (2A) is or are derived from [(2-4)-amino((C2-C4) carboxamide)]((Cι-C5)alkyl), then [(2-4)-amino((C2-C ) carboxamide)]((C2-C5)alkyl) is preferred.
When X and/or Y in Formula (2A) is or are derived from ((C2-C4) carboxamide)[(1-5)-amino((Cι-C5)alkyl)], then ((C2-C4) carboxamide)[(2-5)-amino((C2-C5)alkyl)] is preferred.
It is preferred that R in Formula (3) is (C2-C6)alkyl.
Furthermore, it is preferred that I in Formula (3) is from 1 to 10, or from 1 to 5.
It is preferred that X in Formula (2B) is ((C2-C5)alkyl). In said first group and second group of diamines, it is preferred that the amino acids comprise from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
In said first group of diamines, it is preferred that the diamines are based on amino acids esterified with diols, wherein the diols comprise from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
In said second group of diamines, it is preferred that the diamines are based on amino acids esterified with amino alcohols, wherein the amino alcohols comprise from 2 to 20 carbon atoms, or from 2 to 15 carbon atoms, or more preferably, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
In said third group of diamines, it is preferred that the diamines comprise from 2 to 30 carbon atoms, from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
Further, it is preferred that Ri can be derived from a diisocyanate that comprises from 2 to 30 carbon atoms, from 2 to 20 carbon atoms, from 2 to 15 carbon atoms, from 2 to 10 carbon atoms, or from 2 to 7 carbon atoms.
An important group is that formed when 80 to 100% of R2 comprises segments according to Formula (2A) and/or Formula (2B).
Another important group, from which said 80 to 100% of R2 can be derived, is that of diamines according to Formula (4C). that are, based . pη protected amino acids according to Formula (4A) esterified with compounds (diols) according to Formula (4B) according to the following:
2 R'NRsCOOH (4A) + HOR4OH (4B) → - R'NHR3COOR4OCOR3NHR' + 2H2O → (deprotection, -2H2O) →
→ NH2R3COOR4OCOR3NH2 (4C)
R' is a protective group and amino acids according to Formula (4A) are α- and/or ω-amino acids, examples of such amino acids are glycine (wherein R3 is CH2), alanine, lysine, ornithine, methionine, leucine, isoleucine, phenylalanine, tyrosine, glutamic acid or aspartic acid, or the esters of these with methyl, ethyl, benzyl, phenacyl, tert. -butyl, isopropyl, neopentyl, sec- butyl or tosyl in the α- or ω-position, or from serine with a protected OH- group.
In the case of amino acids whose esters with methyl, ethyl, benzyl, phenacyl, tert. -butyl, isopropyl, neopentyl, sec-butyl or tosyl can be selected either in the α- or ω-position, both variants are included.
Diols according to Formula (4B) can, for example, be selected from ethylene glycol, propylene glycol, butanediol, pentanediol, hexanediol, neopentyl glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, polyethylene glycol (PEG), polytetramethylene oxide diol (PTMOG), 1 ,4-dihydroxymethyl benzene, polypropylene glycol and hydroxitelechelic polybutadiene, together with hybrids of these. Furthermore, compounds according to Formula (4B) can be, for example, hydroxitelechelic oligomers (that is, oligomers with hydroxyl groups at both ends). Examples of such are hydroxitelechelic oligoesters, oligoamides and oligocarbonates. Compounds according to Formula (4B) can also contain other heteroatoms, such as S or N arid/or ester g tiϋps; one example of which is 3-({[(ferf-butoxycarbonyl)amino]actetyl}oxy)-2,2- bis(hydroxymethyl)propyl[(te/τ-butoxycarbonyl)amino] acetate. Another important group from which said 80 to 100% of R2 can be derived is the group of diamines that are derived from esters of protected amino acids according to Formula (4A), wherein the protected amino acids are esterified with amino alcohols. One example is the glycine ester of ethanolamine.
Important criteria for the choice of diamines from which said 80 to 100% of R2 can be derived are the length of the chain of the diamine, the stiffness of the chain, the chemical structure of the ester group and its chemical surroundings. The first two properties, the length of the chain and its stiffness, primarily influence the mechanical properties of said linear polymer, while the latter two, the chemical structure of the ester group and its chemical surroundings, have a major influence on the degradation time of the same.
Other R2, in which said 80 to 100% of R2 is not equal to 100%, can, the same or different, be derived from aliphatic or aromatic diamines, wherein examples of such diamines are primary diamines, for example, ethylene diamine, 1 ,3-diaminopropane, 1 ,3-diamino-2-hydroxypropane, 1 ,3-propandiol-bis-p-amino benzoate or ethylene glycolbisglycine ester diamine.
Said diisocyanates from which Ri can be derived can be commercially available, such as diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4'-diisocyanatobutane or 4,4',-dicyclohexylmethane diisocyanate (H12MDI), or said diisocyanate can be ethyl-2,6- diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4- diisocyanate (TDI) or 1 ,3-bis(isocyanatomethyl)cyclohexane.
A yet further embodiment according to the present invention relates to a linear polymer wherein said linear polymer is a block polymer. An embodiment according to the present invention relates to a linear polymer wherein said 80 to 100% of R , the same or different, can be derived from diamines according to Formula (4C)
NH2R3COOR4OCOR3NH2 (4C),
wherein the diamines according to Formula (4C) are based on protected amino acids according to Formula (4A)
R'NRsCOOH (4A)
that have been esterified with diols according to Formula (4B)
HOR4OH (4B),
wherein R' is a protective group and amino acids according to Formula (4A) are α- and/or ω-amino acids, preferably glycine (wherein R3 is CH2), alanine, lysine, ornithine, methionine, leucine, isoleucine, phenylalanine, tyrosine, glutamic acid or aspartic acid, or the esters of these with methyl, ethyl, benzyl, phenacyl, tert.-butyl, isopropyl, neopentyl, sec-butyl or tosyl in the α- or ω-position, or from serine with a protected OH-group, and
diols according to Formula (4B) are selected from ethylene glycol, propylene glycol, butanediol, pentanediol, hexanediol, neopentyl glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, polyethylene glycol (PEG), polytetramethylene oxide diol (PTMOG) , 1 ,4-dihydroxymethylbenzene, polypropylene glycor and.hydroxitelechelic polybutadiene, and also hybrids of these, and from hydroxitelechelic oligomers, preferably hydroxitelechelic oligoesters, oligoamides or oligocarbonates, wherein the compounds according to Formula (4B) can also contain heteroatoms, such as S or N and/or ester groups. A further embodiment according to the present invention relates to a linear polymer, wherein said 80 to 100% of R2, the same or different, can be derived from diamines that are derived from esters of amino acids with amino alcohols, for example the glycine ester of ethanolamine or 3-({[(fetf-butoxycarbonyl)amino]actetyl}oxy)-2,2- bis(hydroxymethyl)propyl[(te/τ-butoxycarbonyl)amino] acetate.
A yet further embodiment according to the present invention relates to a linear polymer wherein each R1 , the same or different, can be derived from a diisocyanate, which diisocyanate may be commercially available, such as diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4'- diisocyanatobutane or 4,4',-dicyclohexylmethane diisocyanate (Hι2MDI), or said diisocyanate can be ethyl-2,6-diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4-diisocyanate (TDI) or 1 ,3- bis(isocyanatomethyl)cyclohexane.
A yet further embodiment relates to a linear polymer according to Formula (1 ), wherein said 80 to 100% of R2, which 80 to 100% of R2 can be the same or different, can be derived from one or several of
2-aminoethyl 4-aminobutanoate,
4-[(4-aminobutanoyl)oxy]butyl 4-aminobutanoate,
5-[(2S)-2-amino-3-methoxy-3-oxopropyl] 1 -methyl (2S)-2- aminopentanedioate,
5-(2-aminoethyl) 1 -methyl (2S)-2-aminopentanedioate,
5-(3-aminopropyl) 1 -methyl (2S)-2-aminopentanedi.oate,
5-(4-aminobutyl) 1 -methyl (2S)-2-aminopentanedioate, methyl (2S)-2-amino-3-[(3-aminopropanoyl)oxy] propanoate, 2-[(2-aminoacetyl)oxy]ethyl 3-aminopropanoate,
2-[(2-aminoacetyl)oxy]ethyl 4-aminobutanoate,
2-[(2-aminoacetyl)oxy]ethyl aminoacetate, 4-(2-aminoethyl) 1 -methyl (2R)-2-aminobutanedioate, 2-aminoethyl aminoacetate, 4-[(2-aminoacetyl)oxy]butyl aminoacetate, 2-[(3-aminopropanoyl)oxy]ethyl 3-aminopropanoate, 2-[(2-aminoacetyl)oxy]ethyl aminoacetate, methyl (2S)-2-amino-3-[(aminoacetyl)oxy] propanoate, tert-butyl 2,6-diaminohexanoate, benzyl 2,6-diaminohexanoate, 2-aminoethyl [(aminoacetyl)amino] acetate, 2-aminoethyl 3-[(aminoacetyl)amino] propanoate and
2-aminoethyl 3-[(3-aminopropanoyl)amino] propanoate; and
salts, together with all possible stereoisomers either pure or as racemic compounds or as mixtures of stereoisomers, thereof.
Said linear polymer according to the present invention is of the polyurea type and can be prepared from the reaction between one or several different diisocyanates and one or several different diamines, wherein closely equivalent amounts of isocyanate and amino groups are required. The reaction is carried out either in solution or through phase interface polymerisation. In the former case, the reactants are soluble in the solvent while the linear polymer formed can be either soluble or it can precipitate. In the latter case, two immiscible solvents are used, each of which dissolves one of the reactants. Polymerisation occurs at the interface between the phases, from which the name of this procedure is derived.
The molecular weight of the linear polymerjhat js formed can be regulated by modifying the stochiometric balance or by the addition of what are known as chain-stoppers, such as primary or secondary monoamines. The molecular weight distribution is influenced by the method of polymerisation and can be modified by extraction with solvent for, for example, low molecular weight fractions, or by precipitation of high molecular weight fractions from the solution of the linear polymer.
The present invention also relates to a method for preparing said linear polymer, wherein said method comprises polymerisation, in which approximately n moles of one or several different diamines, that is, compounds according to Formula (5)
H2N'
(5)
are linked with approximately n moles of one or several different diisocyanates, that is, compounds according to Formula (6)
NCO NCO
(6)
, wherein
Ri and R2 are defined as they have been previously.
In order to achieve the desired value of molecular weight of said linear polymer according to Formula (1 ), molar ratios for -NH /-NCO are used from 0.95 to 1.05 in the above-described polymerisation.
Polyureas are known to be difficult to process in that the melting point is higher than the" temperature at which' degradation' starts to occur. Due to the tendency of the urea groups to interact via hydrogen bonds, polyureas have a strong tendency to form gels in solution and are difficult to dissolve at all. This can be counteracted to a certain extent by the addition of agents that interact with the urea groups, for example LiCI, LiBr, urea or guanidine hydrochloride. The dissolving can thus take place in dimethylformamide in which LiCI has been dissolved to give a concentration of 1-5%.
The interaction between urea groups in said linear polymer can be influenced by the chemical structure of the urea groups or in their vicinity. Thus, when said linear polymer according to the present invention, through said Ri and/or said 80 to 100% of R2, comprises parts that can be derived from amino acids, substituents of α-carbon atoms in these amino acids lead to steric hindrance, giving weaker hydrogen bonds as a consequence. On the other hand, interaction between stereoisomers can give increased close-packing, and consequently a stronger interaction between polymer chains.
A further embodiment according to the present invention relates to a linear polymer, wherein said Ri and/or said 80 to 100% of R2 comprise parts that can be derived from amino acids, wherein said parts comprise amino acids with substituents on their α-carbon atoms.
Furthermore, the present invention relates to an embodiment of said linear polymer, wherein said 80 to 100% of R2 is 100%, which means that said other R2 is not present, that is, the amount of said other R2 is zero.
A yet further embodiment according to the present invention relates to a linear polymer, wherein the each of said alkyls and each of said alkanoates in Formula (1 ) can, independently of each other, be straight or branched, saturated or unsaturated, and/or substituted with, for example, methyl, phenyl, 4-hydroxyphenyl, 4-aminobutyl, 2-butyl, 2-hydroxy methyl, 3- aminopropyl, 2-aminoethyl,.2-mercaptomethyl, or similar.. -,-. -.-"
Polyureas normally need to be processed from solutions of the polymers. Fibres can thus be prepared by dry or wet spinning, that is, the extrusion of the polymer solution through a mouthpiece with removal of the solvent either by evaporation or by precipitation by non-solvent. Films can be prepared in a similar manner by spreading out the polymer solution in a thin layer on a plate, followed by evaporation and/or precipitation. Naturally, this can take place continuously on a cylinder or an infinite loop in combination with an oven.
One method for preparing hollow articles is by dipping, that is, a mould is repeatedly dipped into the polymer solution and dried and/or coagulated between each dipping. The mould is subsequently removed, which can take place by dissolving it, melting it, or by a mechanical method.
Furthermore, the polymer can be applied to, for example, woven fabric, film or surfaces by, for example, coating, impregnation, lamination or casting, followed by evaporation of the solvent and/or coagulation with a non-solvent.
The present invention also relates to a method for processing said linear polymer, wherein said method comprises preparing fibres through dry or wet spinning of said linear polymer.
A yet further embodiment according to the present invention relates to a method for processing said linear polymer, wherein said method comprises preparing film of said linear polymer or application of said linear polymer onto, for example, woven fabric, film or surfaces by, for example, coating, impregnation, lamination or casting.
A further embodiment according to the present invention relates to a method for processing said linear polymer, wherejn said method comprises dipping of a mould that is dipped into a solution of said linear polymer.
The present invention also relates to the use of said linear polymer described above, in the form of, for example, fibres or film, as, for example, material in implants for humans and animals, for example, as implants for tendons, ligaments, blood vessels, sutures, discs or menisci, for pharmaceutical preparations, in microencapsulation, in suspensions, in emulsions, in porous three-dimensional materials, such as porous polymers materials, or similar.
Porous polymer material is described in, for example, Swedish patent application SE, A, 0004856-1 , which is here referred to in its entirety. SE, A, 0004856-1 describes among other things a method for preparing an open porous polymer material. Swedish patent application SE, C2, 514064, which describes porous films, is also referred to here in its entirety.
Furthermore, the invention relates to the use of said linear polymer according to the present invention in, for example, pharmaceutical preparations, during microencapsulation, in suspensions, in emulsions or similar.
The present invention also relates to the use of said linear polymer as material for artificial blood vessels, in order to prevent adhesions, as an obstacle to adhesion or in order to promote wound healing in humans and animals.
A further embodiment according to the present invention relates to the use of said linear polymer as cell material for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering".
Furthermore, the invention relates to implants, for example, for tendons, ligaments, blood vessels, sutures, discs or menisci, for humans and animals, wherein said implants comprise said linear polymer.
The present invention also relates to pharmaceutical preparations, microencapsules, suspensions, emulsions or porous three-dimensional structures that comprise said linear polymer. The present invention also relates to material for artificial blood vessels, in order to prevent adhesions, as an obstacle to adhesion or in order to promote wound healing in humans and animals, wherein said material comprises said linear polymer.
Furthermore, the present invention relates to a cell material for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering", wherein said cell material comprises said linear polymer.
Polyureas in the form of fibres can be used in ligaments, tendons, sutures or porous three-dimensional structures. In combination with impregnation or lamination, they can be used as, for example, artificial blood vessels or to prevent adhesions.
They can be used in the form of film for, for example, culturing of cells, as an adhesion obstacle or for wound treatment.
As cell material they can be used as the matrix for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering".
The material can be adapted to different applications by varying its degradation time with the aid of the chemical structure.
EXAMPLES
The following examples describe the invention, without in any way limiting it.
Example 1
2-{4-[(ammonioacetyl)oxy] butoxy}-2-oxethanaminium bis(trifl uoroacetate)
a) 4-((2-r(fetf-butoxycarbonv0amino1acetylfoxy)butyl rfe/ -butoxycarbonvDamino] acetate
17.52 g (100 mmol) tert-butyloxycarbonyl glycine was dissolved in 50 ml dichloromethane (DCM) and the solution was added into a jacketed glass reactor cooled to 0°C. 4.5g (50 mmol) butanediol was mixed with 50 ml dichloromethane and added into the reactor under stirring. When the mixture in the reactor had reached 0°C, a solution of 20.6 g (100 mmol) dicyclohexyl carbodiimide (DCC) in 100 ml dichloromethane was added. A catalytic amount of of dimethylaminopyridine (DMAP) was added in order to catalyse the reaction. The temperature in the reactor rose rapidly to 10°C, after which it sank to its original value. The reaction was allowed to proceed for 3 hours at 0°C, after which it was warmed to approximately 30°C for one hour, and then left under stirring at room temperature until the next day. Processing of the reaction mixture commenced with filtration through a 40-100 μm glass filter, wherein the filtration separates out precipitated dicyclohexylurea (DCU). The dichloromethane that passed the filter was extracted with a 1M potassium hydrogen "sulphate solution, followed by extraction with distilled water and with a saturated sodium hydrogen carbonate solution. The dichloromethane phase was then washed three times with distilled water. The washed dichloromethane phase was dried over water-free magnesium sulphate and evaporated to give an oil that crystallised slowly. Yield 80-90%. If the oil contains contaminant in the form of dicyclohexylurea, the oil can be dissolved in ethyl acetate and the contaminant filtered out, in order to then evaporate off the ethyl acetate and regain the final product in a more pure condition. Yield: 16.4 g (approximately 80%).
1HNMR (300 MHz, CDCI3, ppm): 1.42 (s, 9H, OtBu), 1.70-1.75 (m, 2H, CH2), 3.89 (d, 2H, CN2-N ), 4.15-4.20 (m, 2H, CH2-O) and 5.0-5.1 (m, 1 H, NH). C2- symmetry halves the spectrum.
IR: vmax (Solid sample/ATR-FTIR), 3363s (N-H), 1730s (C=O, ester), 1676s (C=O, urethane).
MS: ESMS; m/z (calculated) Cι8H32N2O8 404.455; (obtained) 405.2 [MH+] and 427.2 [MNa+].
b) 2-(4-r(ammonioacetyl)oxy1 butoxyl-2-oxethanaminium bis(trifluoroacetate)
Deprotection of tert-butyloxycarbonyl protective groups by acidolysis.
50 ml dichloromethane (DCM) was added to 12.1g of the product from Step a) (molecular weight (Mw)=404.6, 30 mmol). 20 ml trifluoroacetic acid (TFA) was added under stirring to the partially dissolved substrate. Everything now became dissolved, while the solution took on a faint yellow colour and a powerful production of carbon dioxide could be seen. The procedure was interrupted after 45 minutes by evaporating the reaction to dryness (a yellow oil). 50 ml dry diethylether was added to the oil, and the heterogeneous mixture stirred vigorously. The TFA salt was now precipitated under the stirring and the crystalline substance was washed twice with 50 ml diethyl ether. The crystals were then filtered out from the diethyl ether and vacuum- dried.
Yield: 12.45 g (theoretical 12.96 g ) 96%. IR: vmax (solid sample/ATR-FTIR) 70°C, melted, 3050s (N-H), 1764s (C=O) and 1679s (C=O, TFA).
MS: ESMS; m/z (calculated) C8Hi6N2O4 204.22; (obtained) 204.8 [MH+] and 409.1 [2MH+].
Example 2
4-[(2-ami noacetyl )oxy] butyl ami noacetate
a) 4-F(2-(r(benzyloχy)carbonyl1amino)acetv0oxy]butyl {f(benzyloxy)carbonvπamino) acetate
Benzyloxycarbonylglycine, Z-Gly-OH (20.9 g, 100 mmol), was added into a 0.5 I jacketed reactor. 1 ,4-butane diol (4.56 g, 50 mmol) dispersed in 100 ml dichloromethane (DCM) was then added. A catalytic amount of dimethylaminopyridine (DMAP) was added and the mixture then cooled to 0°C. Dicyclohexyl carbodiimide (DCC) dissolved in 100 ml DCM was added under stirring, wherein dicyclohexylurea (DCU) was precipitated. The mixture was then allowed slowly to reach room temperature, at which it was allowed to proceed under stirring for three days. The reaction mixture was processed by filtering out the DCU that had formed, after which the remaining solution was washed by extraction with a 1M potassium hydrogen sulphate solution, distilled water, saturated sodium hydrogen carbonate and, finally, three times with distilled water. The thus purified organic phase was then dried over water-free magnesium sulphate, filtered and then evaporated to give a colourless oil that crystallised on reaching room temperature.
Yield: 20 g (theoretical 23 g ) 87%. 1HNMR (300 MHz, CDCI3, ppm): 1.71 (m, 2H, CH2), 3.96 (d, 2H, CH2-N), 4.17 (m, 2H, CH2-O), 5.12 (s, 2H, CH2, benzyl), 5.3 (m, 1 H, N-H) and 7.32 (s, 5H, phenyl).
IR: vmaχ (solid sample/ATR-FTIR), 3300s (N-H), 1736s (C=O), 1201s (C-O). MS: ESMS; m/z (calculated) C24H28N2O8 472.488; (obtained) 473.1 [MH+] and 495.1 [MNa+],
b) 4-[(2-aminoacetyl)oxy1butyl aminoacetate
9.44 g (20 mmol) of benzyloxycarbonyl-protected diamine from Step a) were dissolved in a mixture of 100 ml ethyl acetate and 50 ml methanol and transferred to a hydrogenation reactor. A catalytic amount of palladium on active carbon (Pd/C, 10%, Merck) was added under a nitrogen atmosphere, after which the suspension solution was evacuated three times with a water vacuum pump, with respect to dissolved gases. Hydrogen gas was loaded into the reactor between evacuations. A hydrogen gas pressure of 4 bar was then applied under vigorous stirring. Hydrogen gas was rapidly consumed, and hydrogen gas was consequently added at regular intervals. The product started to precipitate out in the reaction after a few hours, and it was consequently necessary to warm it to 40°C. Stirring was continued until the next day when the reaction mixture was warm-filtered through a 1 μm glassfibre filter and evaporated to give an oil that crystallised.
Yield: 4.1 g (100%).
1HNMR (300 MHz/D2O, ppm): 1.56 (m, 2H, CH2), 3.59 (m, 2H, CH2-N), 3.99 (m, 2H, CH2-O) and 4.18 (t, 1 H, partially exchanged, N H). ■■ IR: vmax (solid sample/ATR-FTIR), 3300s (N-H), 1736s (C=O), 1201s (C-O). MS: ESMS; m/z (calculated) C8Hi6N2O4204.22; (obtained) 204.8 [MH+]. Example 3
4-(2-ammonioethoxy)-4-oxo-1 -butanaminium bis(trifluoroacetate)
a) 2-r(ferf-butoxycarbonvπamino1ethyl 4-f(ferf-butoxycarbonv0amino1 butanoate
8.13 g (Mw=203, 40 mmol) of Boc-GABA-OH and 6.45 g (40 mmol, Mw=161 ) of Boc-aminoethanol were added to a reaction vessel together with a small amount of DCM (40 ml). DCC, 8.24 g, 40 mmol dissolved in 40 ml DCM was added at room temperature. A catalytic amount of DMAP was also added. DCU was precipitated within a few seconds. The mixture was stirred overnight. The reaction mixture was filtered and evaporated to give an oil that was dissolved in ethyl acetate and refiltered. The reaction mixture was extracted by washing with sodium hydrogen carbonate solution, dried and evaporated to dryness. The residue crystallised. Yield 11 g, approximately 80%.
1HNMR (300 MHz/CDC , ppm): 1.42 (s, 18H, tBu), 1.8 (m, 2H, -CH2-), 2.36 (t, 2H, -CH2-CO-), 3.15 (d, 2H, -CH2-N, GABA), 3.39 (d, 2H, CH2-N, aminoethanol), 4.16 (d, CH2-O), 4.7 (s, 1 H, NH) and 5.15 (s, 1 H, NH). IR: vmax (Solid sample/ATR-FTIR), 3339s (N-H), 1727s (C=O) and 1685s (C=O, tBu). MS: ESMS; m/z (calculated) Ci6H3oN2O6 346.42; (obtained) 369.2 [MNa+]
b) 4-(2-ammonioethoxy 4-oxo-1 -butanaminium bis(trifluoroacetate)
3.79 g (10.9 mmol) of Boc-protected diamine from Step a) was dissolved in a mixture of 15 ml DCM and 15 ml TFA at room temperature. Carbon dioxide was produced when the reaction mixture was stirred. The reaction mixture was evaporated to dryness after two hours. The residue, which contained an excess of TFA, was precipitated at alkali pH by a sodium carbonate solution and extracted three times with chloroform. The chloroform phases were combined, dried, and evaporated to dryness. The residue, an oil that crystallised. Yield: 3.3 g (theoretical 4.08 g ) 81%.
IR: vmax (Solid sample/ATR-FTIR), 3340s, 2927s, 2855s, 1686s (C=O), 1641 s (C=O, TFA). MS: ESMS; m/z (Calculated) C64N2θ2 146.19 ; obtained 146.8 [MH+].
Example 4
4-[(4-aminobutanoyl)oxy]butyl 4-aminobutanoate
a) 4-f(4-(r(benzyloxy)carbonvnaminorbutanoyl) oxylbutyl 4-(f(benzyloxytoarbonvπamino) butanoate
7.99 g (33.6 mmol, Mw=237) Z-GABA-OH and 1.51 g (16.8 mmol, Mw=90.13) butanediol were mixed in a reactor together with 100 ml DCM and a catalytic amount of DMAP. The mixture was cooled to 0°C, after which 7.2 g (approximately 35 mmol, Mw=206) of DCC dissolved in 50 ml DCM was added under stirring. DCU started to precipitate immediately. The mixture was allowed to reach room temperature slowly and stirred overnight.
The reaction mixture was warmed for a short period to 30°C before processing. After cooling, the DCU was filtered out and the residue washed by extraction with potassium hydrogen sulphate (1 M), distilled water, sodium hydrogen carbonate (saturated) and three times with distilled water. The organic phase was then dried over water-free magnesium sulphate and evaporated to give an oil. The oil was dissolved in absolute ethanol and placed in the cold to crystallise. The crystals were filtered out and dried. Yield: approximately 8 g (theoretical 8.8 g) 90%. 1HNMR (300 MHz/CDCIs, ppm): 1.69 (d, undissolved, 2H, O-C-CH2), 1.82 (m, 2H, C-CH2-C), 2.35 (t, 2H, CH2-CO), 3.22 (m, 2H, N-CH2), 4.07 (d, undissolved, 2H, O-CH2), 4.94 (m,1 H, N-H), 5.08 (s, 2H, benzyl) and 7.3 (s, 5H, phenyl). MS: ESMS; m/z (calculated) C28H36N2O6 528.59; (obtained) 529.2 [MH+] and 551.2 [MNa+].
IR: vmax (Solid sample/ATR-FTIR), 3332s (N-H), 1722s (C=O) and 1686s (C=0).
b) 4-r(4-aminobutanoyl)oχy]butyl 4-aminobutanoate
Approximately 8 g (approximately 16 mmol, Mw=528) of the product from Step a) was dissolved in absolute ethanol. A catalytic amount of palladium on active carbon (Pd/C 10%) was added and dissolved gases evacuated from the mixture. A hydrogen gas pressure of 4 bar was then applied and the mixture stirred vigorously. When no more hydrogen gas was consumed in the reaction mixture, the procedure was interrupted and the catalyst filtered out. The residual solution was evaporated to an oil, 6 g, which dried slowly. Yield: approximately 3.5 g (80%).
IR: vmax (Solid sample/ATR-FTIR), 3300s (N-H) and 1682s (C=O). MS: ESMS; m/z (calculated) Cι2H2 N2O4260.33; (obtained) 261 [MH+].
Example 5
5-[(2S)-2-amino-3-methoxy-3-oxopropyl] 1 -methyl (2S)-2- aminopentandioate
a) 5-((2S V2-(r(benzyloxy)carbonyl1aminol-3-methoxy-3-oxoc-ropy0 1 -methyl (2S)-2-{f(benzyloxy)carbonyl]amino)pentandioate
8.86 g (30 mmol, Mw=295.3) Z-Glu-OMe and 7.6 g (30 mmol, Mw=253.3) Z- Ser-OMe were dissolved in 100 ml DCM, after which a catalytic amount of DMAP was added. The mixture was cooled to 0°C, and 6.39 g (31 mmol, Mw=206) of DCC dissolved in 20 ml DCM was added under stirring. The mixture was allowed to reach room temperature and was stirred overnight. DCU precipitated out from the reaction mixture slowly.
The mixture was processed after being warmed to 30°C for approximately one hour. The residue was dissolved in ethyl acetate after filtering and evaporation, on which further DCU precipitated out. The product mixture was allowed to stand for three days before being refiltered. The reaction mixture was washed by extraction with potassium hydrogen sulphate (1 M), distilled water, sodium hydrogen carbonate (saturated) and finally three times with distilled water. The organic phase was then dried over water-free magnesium sulphate, filtered and evaporated to dryness.
Yield: 17 g (theoretical 16 g).
1HNMR (300 MHz/CDCIs, ppm): 1.92 (m, 2H, C-CH2-C), .2.18 (m, 1 H, -CH- CO), 2.38 (m, 2H, CH2-CO), 3.72 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 4.38 (m, 2H, CH2-O), 4.64 (m, 1 H, α-H), 5.06 (s, 2H, benzyl), 5.11 (s,2H, benzyl), 5.43 (d, 1 H , N-H), 5.91 (d, 1 H, N-H), 7.32 (s, 5H, phenyl) and 7.324 (s, 5H, phenyl). IR: max (Solid sample/ATR-FTIR), 3330s (N-H) and 1720s (C=O, broad).
MS: ESMS; m/z (calculated) C26H30N2O10 530.52; (obtained) 531.3 [MH+] and 553.3 [MNa+].
b) 5-f(2S)-2-amino-3-methoxy-3-oxopropyll 1 -methyl (2S)-2- aminopentandioate
Benzyloxycarbonyl-protected diamine, 16 g, 30 mmol, Mw=530.5, was dissolved in 50 ml absolute ethanol and a catalytic amount of palladium on active carbon (Pd/C 10%) was added, after which dissolved gases were evacuated from the mixture by applying a water vacuum. A hydrogen gas pressure of 2.5 bar was then applied and the mixture stirred vigorously. When no further hydrogen gas was consumed in the reactor on the following day, the procedure was interrupted and the contents filtered through celite and evaporated to an oil.
Yield: 7.65 g (theoretical 7.86 g) 97%
IR: Vmax(Solid sample/ATR-FTIR), 3360s (N-H), 3280s (N-H), 1733s (C=O), 1676s (C=O) and 1204s (C-O).
MS: ESMS; m/z (calculated) Cι0H18N2O6 262.26; (obtained), 262.9 [MH+] and 284.9 [MNa+].
Example 6
2-{2-[(aminoacetyl)oxy]ethoxy}-2-oxoetanaminium dichloride
a) 2-({2-f(te/t-butoxycarbonvπamino1acetyl)oxy ethyl rfetτ-butoxycarbonyl)amino)acetate
35.04 g (200 mmol) tert-butyloxycarbonylglycine and 6.21 g (100 mmol) ethylene glycol were dissolved in 300 ml dichloromethane (DCM). The mixture was cooled to 0°C, and a catalytic amount of dimethylaminopyridine (DMAP) was then added. A solution of 41.4 g (200 mmol) dicyclohexyl carbodiimide (DCC) in 150 ml DCM was then added under vigorous stirring. The reaction was then allowed to reach room temperature and was allowed to proceed until the next day.
Processing of the reaction commenced with filtration, followed by evaporation of the filtrate and its dissolution in approximately 20 ml ethyl acetate. This solution was washed with 1 M KHSO4, distilled water, saturated NaHCO3, and then three times with distilled water. The solution was then dried over magnesium sulphate and evaporated to give an oil that crystallised. Yield 35 g. The crystals were recrystallised from warm ethyl acetate (100 ml) and then finally mixed to a slurry in n-hexane and filtered.
Yield: 33 g (theoretical 37.6 g) 88%.
1H NMR (300 MHz, CDCI3, ppm): 1.42 (s, 9H, OtBu), 3.92 (d, 2H, N-CH2- CO), 4.36 (s, 2H, O-CH2-C) and 5.1 (m, 1 H, N-H). C2-symmetry halves the NMR spectrum.
IR: vmax (solid sample/ATR-FTIR), 3340s (N-H), 1762s (C=0, ester) and 1673s (C=O, urethane).
MS: ESMS; m/z (calculated) d6H28N2O8 376.18457; (obtained) 377 [M+H] + and 399.1 [M+Na]+ .
b 2-(2-r(aminoacetvDoxy1ethoxy)-2-oxoetanaminium dichloride
13.2 g (35 mmol) of the Boc-protected diamine from Step a) were treated with 50 ml 5M HCI in IPA under nitrogen gas in a round-bottomed flask under stirring. The mixture thickened rapidly, and 50 ml isopropylalcohol (IPA) were consequently added. The mixture was evaporated to dryness after 1 hour. The evaporated reaction mixture was triturated with diethyl ether and re-evaporated. The residue after evaporation was a colourless crystalline powder. The yield was quantitative.
1H NMR (300 MHz, DMSO, ppm): 3.85 (s, 2H, N-CH2-CO), 4.4 (s, 2H, O- CH2) and 8.45 (s, 3H, NH3 +). C2-symmetry halves the NMR spectrum.
IR: vmax (Solid sample/ATR-FTIR), 2950s (N-H) and 1744s (C=0).
MS: ESMS; m/z (calculated) C62N2O4 (free base) 176.07971 ; (obtained) 176.9 [M+H]+ and 198.9 [M+Na]+.
Example 7
Preparation of a linear polymer according to the present invention through the polymerisation of L-lysine diisocyanate (LDI) with 2-[(2- aminoacetyl)oxy]ethyl aminoacetate (the product from Example 6)
Figure imgf000031_0001
Procedure
Glass equipment was dried at 77°C -2 hours. LDI was weighed out into a 250 ml flanged flask, nitrogen gas was applied.
2-{2-[(aminoacetyl)oxy]ethoxy}-2-oxoetanaminium dichloride (the product from Example 6) was weighed out into a 25 ml beaker and dissolved in deionised water. Chloroform (21 g, 74% of the total quantity) was added to the weighed LDI and stirring commenced. Triethylamine was weighed out and dissolved in the remaining amount of chloroform (7.4 g). When it appeared that all LDI has dissolved in the chloroform
(2-{2-[(aminoacetyl)oxy]ethoxy}-2-oxoetanaminium) dichloride and water were added. Triethylamine and chloroform were added dropwise using a pipette during approximately 3 minutes. Lumps of gel could be observed in the solution.
Acetone (10 ml) was added after stirring for 20 minutes, and then deionised water (200 ml). The water was separated out and new water (200 ml) added.
This water also was separated out and the sticky mass of polymer dried in a vacuum oven.
mPoiymer : 0.80 g Yield: - 78%
The dried polymer was dissolved in DMSO to a concentration of 18% and it was possible to cast a film. A sample of the dried polymer was subjected to analysis by SEC ("Size Exclusion Chromatography"). According to SEC (using an RI detector) the polymer has a peak after approximately 15.0 minutes, which corresponds to a molecular weight of 180,000 relative to a polystyrene standard. Example 8
Preparation of a linear polymer according to the present invention through the polymerisation of 4,4 -diphenylmethane diisocyanate (MDI) with 2-[(2-aminoacetyl)oxy]ethyl aminoacetate (the product from Example 6)
Figure imgf000033_0001
Procedure Glass equipment was dried at 77°C for approximately 2 hours.
MDI was weighed out into a 250 ml flanged flask, nitrogen gas was applied.
2-{2-[(aminoacetyl)oxy]ethoxy}-2-oxoetanaminium dichloride (the product from Example 6) was weighed out into a 25 ml beaker and dissolved in deionised water. Chloroform (21 g, 74% of the total quantity) was added to the weighed MDI and stirring commenced. Triethylamine was weighed out and dissolved in the remaining amount of chloroform (7.4 g). When it appeared that all MDI had dissolved in the chloroform, 2-2-[(aminoacetyl)oxy]ethoxy}-2-oxoetanaminium dichloride and water were added. Triethylamine and chloroform were added dropwise using a pipette during approximately 3 minutes, under stirring. Acetone (8 ml) was added after stirring for 20 minutes, and then deionised water (200 ml). The water was separated out and new water (200 ml) added. This water also was separated out and the organic phase was then evaporated in a Rotavapor. A yellow-white powder was obtained.
mpoiymer : 0.814 g Yield: -70%
The dried polymer was dissolved in DMSO to a concentration of 18% and it was possible to cast a film. A sample of the dried polymer was subjected to analysis by SEC. According to SEC (using UV and RI detectors) the polymer has a peak after approximately 14.13 minutes, which corresponds to a molecular weight of 400,000 relative to a polystyrene standard.
Example 9
Degradation experiments of a linear polymer according to the present invention wherein the polymer was prepared in analogy with Example 7 by the polymerisation of L-lysine diisocyanate (LDI) with 4-[(2-aminoacetyl)oxy]butyl aminoacetate
4-[(2-aminoacetyl)oxy]butyl aminoacetate was prepared in analogy with the preparation according to Examples 1-6. Thereafter, a linear polymer is prepared in analogy with Example 7 by the polymerisation of L-lysine diisocyanate (LDI) with 4-[(2-aminoacetyl)oxy]butyl aminoacetate. The linear polymer prepared was in the form of a film and had a molecular weight of 450,000 relative to a polystyrene standard. The polymer, was held in a bath with phosphate buffer (at pH 7.0) at 67°C. The polymer film had disintegrated after seven days, that is, it was broken down to such a degree that it was not possible to obtain a sample for analysis by SEC. Example 10
Degradation experiments of a linear polymer according to the present invention wherein the polymer was prepared in analogy with Example 8 by the polymerisation of 4,4 -diphenylmethane diisocyanate (MDI) with 4-[(2-aminoacetyl)oxy]butyl aminoacetate
4-[(2-aminoacetyl)oxy]butyl aminoacetate was prepared in analogy with the preparation according to Examples 1-6. Thereafter, a linear polymer is prepared in analogy with Example 8 by the polymerisation of 4,4'-diphenylmethane diisocyanate (MDI) with the HCI salt of 4-[(2- aminoacetyl)oxy]butyl aminoacetate. The linear polymer prepared was in the form of a film and had a molecular weight of 400,000 relative to a polystyrene standard. The polymer was held in a bath with phosphate buffer (at pH 7.0) at 67°C. A sample for SEC analysis was taken after five days in the phosphate buffer, wherein the molecular weight was reduced to 175,000 relative to a polystyrene standard.
Example 11
Degradation experiments of a linear polymer according to the present invention wherein the polymer was prepared in analogy with Example 8 by the polymerisation of 4,4'-diphenylmethane diisocyanate (MDI) with 4-[(2-amino-4-methylpentanoyl)oxy]butyl 2-amino-4- methylpentanoate
4-[(2-amino-4-methylpentanoyl)oxy]b,utyl . , 2-amino-4-methylpentanoate is prepared in analogy with the preparation according to Examples 1-6. Thereafter, a linear polymer is prepared in analogy with Example 8 by the polymerisation of 4,4'-diphenylmethane diisocyanate (MDI) with the HCI salt of 4-[(2-amino-4-methylpentanoyl)oxy]butyl 2-amino-4-methylpentanoate. The linear polymer prepared was in the form of a film and had a molecular weight of 435,000 relative to a polystyrene standard. The polymer was held in a bath with phosphate buffer (at pH 7.0) at 67°C. SEC analysis was carried out after 55 days, and the molecular weight had then been reduced to between 200,000 and 300,000 relative to a polystyrene standard.

Claims

1. A linear polymer with a molecular weight of at least 104 Dalton, which linear polymer consists of internally and linearly linked sequences, which sequences can be described according to Formula (1)
Figure imgf000037_0001
(1) wherein
80 to 100% of R2, which 80 to 100% of R2 can be the same or different, comprise a segment according to Formula (2A)
Figure imgf000037_0002
wherein
E is oxygen or nitrogen,
X and Y, which X and Y can be the same or different, are (Cι-C5)alkyl, or are derived from ((CrC4)alkyl)[(2-4)-amino((C2-C ) alkanoate)], [(1 -4)-amino((Cι-C4)alkyl)]((C2-C4) alkanoate), [(2-4)-amino((C2-C4) alkanoate)]((Cι-C5)alkyl), ((C2-C4) alkanoate)[(1-5)-amino((Cι-C5)alkyl)], ((Cι-C4)alkyl)[(2-4)-amino((C2-C4) carboxamide)], [(1 -4)-amino((Cι-C )alkyl)]((C2-C4) carboxamide), [(2-4)-amino((C2-C4) carboxamide)]((Cι-C5)alkyl) or from ((C2-C4) carboxamide)[(1 -5)-amino((Cι-C5)alkyl)], and provided that Y is not Ci -alkyl, or
Y is derived from a substituent according to Formula (3)
Figure imgf000038_0001
(3)
wherein R is (Cι-C )alkyl, and
I is from 1 to 20, and X is as has been defined above;
said 80 to 100% of R2, the same or different, comprise a segment according to Formula (2B)
Figure imgf000038_0002
wherein X' is ((Cι-C5)alkyl) and
Z is hydrogen, (Cι-C4)alkyl, benzyl, tert. -butyl, phenacyl, isopropyl, neopentyl, sec-butyl or tosyl; and/or
said 80 to 100% of R2, the same or different, can be derived from a first group of diamine that are based on amino acids esterified with diols, and/or from a second group of diamines that is based on amino acids esterified with amino alcohols; and,
when not 100% of R2 comprise a segment according to Formula (2A) or (2B), or can be derived from said first or second groups of diamines, each other R2 can be derived from a third group of diamines that are aliphatic or aromatic diamines; and
each Ri, the same or different, can be derived from a diisocyanate, wherein said diisocyanate can be diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4'-diisocyanatobutane or 4,4',-dicyclohexylmethane diisocyanate (H12MDI), or said diisocyanate can be ethyl-2,6- diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4- diisocyanate (TDI) or 1 ,3-bis(isocyanatomethyl)cyclohexane.
2. The linear polymer according to claim 1 , characterised in that E in the segment according to Formula (2A) is oxygen, and/or
X and Y, the same or different, are (Cι-Cs)alkyl, or are derived from ((Cι-C4)alkyl)[(2-4)-amino((C2-C ) alkanoate)], [(1 -4)-amino((Cι-C4)alkyl)]((C2-C4) alkanoate), [(2-4)-amino((C2-C4) alkanoate)]((C C5)alkyl) or ((C2-C4) alkanoate)[(1-5)-amino((Cι-C5)alkyl)].
3. The linear polymer according to claim 1 or 2, characterised in that said linear polymer is degradable.
4. The linear polymer according to any one of claims 1 to 3, characterised in that said linear polymer is a block polymer.
5. The linear polymer according to any one of claims 1 , 3 or 4 characterised in that said 80 to 100% of R2, the same or different, can be derived from diamines according to Formula (4C)
NH2R3COOR4OCOR3NH2 (4C),
wherein the diamines according to Formula (4C) are based on protected amino acids according to Formula (4A)
R'NRsCOOH (4A)
that have been esterified with diols according to Formula (4B)
HOR4OH (4B),
wherein R' is a protective group and amino acids according to Formula (4A) are α- and/or ω-amino acids, preferably glycine (wherein R3 is CH2), alanine, lysine, omithine, methionine, leucine, isoleucine, phenylalanine, tyrosine, glutamic acid or aspartic acid, or the esters of these with methyl, ethyl, benzyl, phenacyl, tert.-butyl, isopropyl, neopentyl, sec-butyl or tosyl in the α- or ω-position, or from serine with a protected OH-group, and
diols according to Formula (4B) are selected from ethylene glycol, propylene glycol, butane diol, pentane diol, hexane diol, neopentyl glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, polyethylene glycol (PEG), polytetramethylene oxide diol (PTMOG) , 1 ,4-dihydroxymethylbenzene, polypropylene glycol and hydroxitelechelic polybutadiene, and also hybrids of these, and from hydroxitelechelic oligomers, preferably hydroxitelechelic oligoesters, oligoamides or oligocarbonates, wherein the compounds according to Formula (4B) can also contain heteroatoms, such as S or N and/or ester groups.
6. The linear polymer according to any one of claims 1 , 3 or 4 characterised in that said 80 to 100% of R , the same or different, can be derived from diamines that are derived from esters of amino acids with amino alcohols.
7. The linear polymer according to any one of claims 1 to 6, characterised in that each Ri, the same or different, can be derived from a diisocyanate, which can be commercially available, such as diphenylmethyl diisocyanate (MDI), hexamethylene diisocyanate (HDI), 1 ,4'-diisocyanatobutane or 4,4',-dicyclohexylmethane diisocyanate (H12MDI), or said diisocyanate can be ethyl-2,6-diisocyanatohexanoate (LDI), isophorone diisocyanate (IPDI), toluene-2,4-diisocyanate (TDI) or 1 ,3-bis(isocyanatomethyl)cyclohexane.
8. The linear polymer according to any one of claims 1 , 3, 4 or 7, characterised in that said 80 to 100% of R2, which 80 to 100% of R2 can be the same or different, can be derived from one or several of
2-aminoethyl 4-aminobutanoate,
4-[(4-aminobutanoyl)oxy]butyl 4-aminobutanoate, 5-[(2S)-2-amino-3-methoxy-3-oxopropyl] 1 -methyl
(2S)-2-aminopentanedioate,
5-(2-aminoethyl) 1 -methyl (2S)-2-aminopentanedioate,
5-(3-aminopropyl) 1 -methyl (2S)-2-aminopentanedioate,
5-(4-aminobutyl) 1 -methyl (2S)-2-aminopentanedioate, methyl (2S)-2-amino-3-[(3-aminopropanoyl)oxy] propanoate,
2-[(2-aminoacetyl)oxy]ethyl 3-aminopropanoate,
2-[(2-aminoacetyl)oxy]ethyl 4-aminobutanpate,
2-[(2-aminoacetyl)oxy]ethyl aminoacetate,
4-(2-aminoethyl) 1 -methyl (2R)-2-aminobutanedioate, 2-aminoethyl aminoacetate,
4-[(2-aminoacetyl)oxy]butyl aminoacetate,
2-[(3-aminopropanoyl)oxy]ethyl 3-aminopropanoate, 2-[(2-aminoacetyl)oxy]ethyl aminoacetate, methyl (2S)-2-amino-3-[(aminoacetyl)oxy] propanoate, tert-butyl 2,6-diaminohexanoate, benzyl 2,6-diaminohexanoate, 2-aminoethyl [(aminoacetyl)amino] acetate,
2-aminoethyl 3-[(aminoacetyl)amino] propanoate and 2-aminoethyl 3-[(3-aminopropanoyl)amino] propanoate; and
salts, together with all possible stereoisomers either pure or as racemic compounds or as mixtures of stereoisomers, thereof .
9. The linear polymer according to any one of the preceding claims, characterised in that said Ri and/or said 80 to 100% of R2 comprise parts that can be derived from amino acids, wherein said parts comprise amino acids with substituents on their α-carbon atoms.
10. The linear polymer according to any one of the preceding claims, characterised in that said 80 to 100% of R2 is 100%.
11. The linear polymer according to any one of the preceding claims characterised in that said each alkyl and said each alkanoate in Formula (1 ) can, independently of each other, be straight or branched, saturated or unsaturated, and/or substituted with, for example, methyl, phenyl, 4- hydroxyphenyl, 4-aminobutyl, 2-butyl, 2-hydroxymethyl, 3-aminopropyl, 2- aminoethyl, 2-mercaptomethyl, or similar.
12. A method -for preparing a linear polymer according to any one of the preceding claims, characterised in that said method comprises polymerisation, in which approximately n moles of one or several different compounds according to Formula (5)
Figure imgf000042_0001
are linked with approximately n moles of one or several different compounds according to Formula (6)
/R1^ NCO NCO
(6)
, wherein
Ri and R2 are defined according to any one of the preceding claims.
13. A method for processing a linear polymer according to any one of claims 1 to 11 , characterised in that said method comprises the preparation of fibres by dry or wet spinning of said linear polymer.
14. A method for processing a linear polymer according to any one of claims 1 to 11 , characterised in that said method comprises preparation of film of said linear polymer or application of said linear polymer onto woven material, film or surfaces by coating, impregnation, lamination or casting.
15. A method for processing a linear polymer according to any one of claims 1 o 11 , characterised in that said method comprises dipping a mould that is dipped into a solution of said linear polymer.
16. Use a linear polymer according to any one of claims 1 to 11 , in the form of, for example, fibres or film as, for example, material in implants for humans and animals, for example, as implants for tendons, ligaments, blood vessels, sutures, discs or menisci, for pharmaceutical preparations, in microencapsulation, in suspensions, in emulsions, in porous three- dimensional structures, such as porous polymer materials, or similar.
17. The use of a linear polymer according to any one of claims 1 to 1 in pharmaceutical preparations, during microencapsulation, in suspensions, in emulsions or similar.
18. The use of a linear polymer according to any one of claims 1 to 11 , in material for artificial blood vessels, material for preventing adhesions, material that prevents adhesion or material for promoting wound healing in humans and animals.
19. Use of a linear polymer according to any one or claims 1 to 11 , in a cell material for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering".
20. Implants, for example tendons, ligaments, blood vessels, discs or menisci, for humans and animals, characterised in that said implants comprise a linear polymer according to any one of claims 1 to 11.
21. Pharmaceutical preparations, microencapsules, suspensions, emulsions or porous three-dimensional structures that comprise a linear polymer according to any one of claims 1 to 11.
22. Material for artificial blood vessels, for preventing adhesions, as - obstacles to adhesion or for promoting wound healing in humans and animals, characterised in that said material comprises a linear polymer according to any one of claims 1 to 11.
23. Cell material for culturing of cells, menisci, discs and other applications that are covered by the concept of "tissue engineering", characterised in that said material comprises a linear polymer according to any one of claims 1 to 11.
PCT/SE2001/002901 2000-12-29 2001-12-27 New linear block polymer WO2002053616A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0004925-4 2000-12-29
SE0004925A SE0004925L (en) 2000-12-29 2000-12-29 Chemical compounds
SE0101523-9 2001-04-27
SE0101523A SE0101523L (en) 2000-12-29 2001-04-27 Linear polymer

Publications (1)

Publication Number Publication Date
WO2002053616A1 true WO2002053616A1 (en) 2002-07-11

Family

ID=26655356

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/SE2001/002901 WO2002053616A1 (en) 2000-12-29 2001-12-27 New linear block polymer
PCT/SE2001/002904 WO2002053526A1 (en) 2000-12-29 2001-12-27 New compounds for use as intermediates in linear block polymer and new linear block polymer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/002904 WO2002053526A1 (en) 2000-12-29 2001-12-27 New compounds for use as intermediates in linear block polymer and new linear block polymer

Country Status (3)

Country Link
AR (2) AR032053A1 (en)
SE (1) SE0101523L (en)
WO (2) WO2002053616A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115433098A (en) * 2022-09-19 2022-12-06 西南石油大学 Environment-friendly amine inhibitor and preparation method thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4398724B2 (en) 2001-07-13 2010-01-13 ビーティージー・インターナショナル・リミテッド Pharmaceuticals containing pyrimidine derivatives
US10189773B2 (en) * 2010-05-07 2019-01-29 Medicus Biosciences, Llc In-vivo gelling pharmaceutical pre-formulation
US10111985B2 (en) 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US11083821B2 (en) 2011-08-10 2021-08-10 C.P. Medical Corporation Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
WO2013170195A1 (en) 2012-05-11 2013-11-14 Medicus Biosciences, Llc Biocompatible hydrogel treatments for retinal detachment
US20140271767A1 (en) 2013-03-14 2014-09-18 Medicus Biosciences Llc Biocompatible hydrogel polymer matrix for delivery of cells
EP3101064B1 (en) * 2014-01-31 2020-07-15 Seikagaku Corporation Diamine crosslinking agent, acidic polysaccharide crosslinked body, and medical material

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049632A (en) * 1976-07-14 1977-09-20 Armstrong Cork Company Chain extending polyurethanes with a large excess of water
EP0129396A2 (en) * 1983-06-16 1984-12-27 Pfizer Hospital Products Group, Inc. Biocompatible poly-(ether-urethane-urea) and process for its preparation
US4689353A (en) * 1986-02-21 1987-08-25 The Dow Chemical Company Hydroxy and amino-functional polyahls containing carbonate, urethane and/or urea moieties
US5236966A (en) * 1989-08-15 1993-08-17 British Technology Group Limited Polymeric materials
WO1997022643A1 (en) * 1995-12-15 1997-06-26 Artimplant Development Artdev Ab Linear block polymer comprising urea and urethane groups, method for the production of linear block polymers and use of the block polymers as implants
WO2000045869A1 (en) * 1999-02-02 2000-08-10 Artimplant Ab A film for medical use, consisting of linear block polymers of polyurethane and a method for the production of such a film
US6221997B1 (en) * 1997-04-28 2001-04-24 Kimberly Ann Woodhouse Biodegradable polyurethanes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939200A (en) * 1966-01-06 1976-02-17 Rohm And Haas Company Aliphatic acyl-containing amine hydrochlorides
US3567763A (en) * 1966-01-06 1971-03-02 Rohm & Haas Ester polyisocyanates
GB1251718A (en) * 1968-03-15 1971-10-27

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049632A (en) * 1976-07-14 1977-09-20 Armstrong Cork Company Chain extending polyurethanes with a large excess of water
EP0129396A2 (en) * 1983-06-16 1984-12-27 Pfizer Hospital Products Group, Inc. Biocompatible poly-(ether-urethane-urea) and process for its preparation
US4689353A (en) * 1986-02-21 1987-08-25 The Dow Chemical Company Hydroxy and amino-functional polyahls containing carbonate, urethane and/or urea moieties
US5236966A (en) * 1989-08-15 1993-08-17 British Technology Group Limited Polymeric materials
WO1997022643A1 (en) * 1995-12-15 1997-06-26 Artimplant Development Artdev Ab Linear block polymer comprising urea and urethane groups, method for the production of linear block polymers and use of the block polymers as implants
US6221997B1 (en) * 1997-04-28 2001-04-24 Kimberly Ann Woodhouse Biodegradable polyurethanes
WO2000045869A1 (en) * 1999-02-02 2000-08-10 Artimplant Ab A film for medical use, consisting of linear block polymers of polyurethane and a method for the production of such a film

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115433098A (en) * 2022-09-19 2022-12-06 西南石油大学 Environment-friendly amine inhibitor and preparation method thereof

Also Published As

Publication number Publication date
SE0101523D0 (en) 2001-04-27
AR032222A1 (en) 2003-10-29
AR032053A1 (en) 2003-10-22
WO2002053526A1 (en) 2002-07-11
SE0101523L (en) 2002-06-30

Similar Documents

Publication Publication Date Title
US4892733A (en) Biodegradable synthesis polypeptide and its therapeutic use
US4888398A (en) Biodegradable polypeptide and the use thereof for the gradual release of drugs
EP0927196B1 (en) Polymers containing polysaccharides such as alginates or modified alginates
US5665831A (en) Biocompatible block copolymer
EP2298235B1 (en) Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices
AU670030B2 (en) Water insoluble derivatives of polyanionic polysaccharides
EP1948713B1 (en) Functionalized amino acids and absorbable polymers therefrom
Deng et al. Biodegradable functional poly (ester amide) s with pendant hydroxyl functional groups: Synthesis, characterization, fabrication and in vitro cellular response
WO2002053616A1 (en) New linear block polymer
FR2707992A1 (en) New organic products containing reactive thiol functions, one of their preparation processes and the biomaterials containing them.
WO2003062298A1 (en) Co-poly(ester amide) and co-poly(ester urethane) compositions which exhibit biodegradability, methods for making same and uses for same
WO1994013731A1 (en) New collagen derivatives, production process and application to the preparation of biomaterials
EP3101064B1 (en) Diamine crosslinking agent, acidic polysaccharide crosslinked body, and medical material
EP1806377A1 (en) Temperature-responsive depsipeptide polymer
Hayashi et al. Enzymatic hydrolysis of copoly-(N-hydroxyalkyll-glutamine/γ-methyl l-glutamate) fibres
US5248761A (en) Amino acid terminated polyesters having predetermined monomeric sequence
US20100015205A1 (en) Biocompatible amino acid anhydride polymers
Katsarava et al. Pseudo-proteins and related synthetic amino acid based polymers
EP1353968B1 (en) Linear block copolymer
Kimura et al. Fluorescence Studies on Self-association of Biodegradable Pyrene-labeled Poly (L-lysine) Grafted with Poly (caprolactone)
Zavradashvili et al. Synthesis of Biomimetic Polymers Based on Nonproteinogenic α-Amino Acids
Kantaria et al. HETEROCHIAIN POLYMERS via TRICOMPONENT CLICK STEP-GROWTH POLYMERIZATION: OPTIMIZATION OF THE REACTION
US20120158127A1 (en) Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices
Yamaoka et al. Surface Modification of Poly (Lactic Acid) with Bioactive Peptides
AU2002217694A1 (en) Linear block polymer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP